Theodora McCormick, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Newark and Princeton offices, was quoted in Wolters Kluwer Health Law Daily, in the Strategic Perspectives column titled “No Longer ‘Medical Backwater’: FTC Homing in on Homeopathy.”
Following is an excerpt:
McCormick believes that “the FTC [has] provided fairly compelling survey evidence in support of its argument that consumers are confused about just what homeopathy is and what homeopathic products do.” McCormick thinks “this confusion stems from the fact that homeopathy is a centuries-old form of medicine that until recently has not been subject to much scientific scrutiny. Moreover, homeopathic remedies are frequently sold alongside conventional over-the-counter drugs in pharmacies and supermarkets, which might lead the average consumer to purchase a homeopathic remedy when what they are really looking for is a standard OTC drug.”
McCormick also recognizes that “there is a risk that consumers might think the FDA has approved the efficacy of homeopathic products.” She believes that including “a disclaimer [on the labeling] might go a long way towards reducing the percentage of consumers who erroneously believe that the FDA has approved the efficacy of homeopathic products.”
